However, the long-term use of DPP4 inhibitors for the treatment of type II diabetes has been debated and one study suggests that patients with type II diabetes treated with a DPP4 inhibitor do not have a higher risk of developing cancers than patients treated with a placebo or other drugs [118]. Here, DPP4 is linked to cancer.